Research programme: oncolytic viral immunotherapies - Turnstone Biologics

Drug Profile

Research programme: oncolytic viral immunotherapies - Turnstone Biologics

Alternative Names: MG1-E6E7; MG1-HPV; MG1-Maraba virotherapy

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Turnstone Biologics
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Prostate cancer

Most Recent Events

  • 16 May 2018 Roche enters into a clinical supply agreement with Turnstone Biologics to provide atezolizumab for use in combination with MG1 HPV
  • 16 May 2018 The US FDA approves IND application for MG1 HPV in Solid tumours (Human papilloma virus positive)
  • 16 May 2018 Turnstone Biologics plans a phase I/II trial for Solid tumours (Combination therapy, human papilloma virus positive) in USA in the second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top